Shaanxi Panlong Pharmaceutical Group Limited By Share Past Earnings Performance
Past criteria checks 5/6
Shaanxi Panlong Pharmaceutical Group Limited By Share has been growing earnings at an average annual rate of 11.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 14% per year. Shaanxi Panlong Pharmaceutical Group Limited By Share's return on equity is 7.8%, and it has net margins of 12.4%.
Key information
11.1%
Earnings growth rate
9.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 14.0% |
| Return on equity | 7.8% |
| Net Margin | 12.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shaanxi Panlong Pharmaceutical Group Limited By Share makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 965 | 120 | 435 | 21 |
| 31 Dec 23 | 981 | 110 | 419 | 20 |
| 30 Sep 23 | 997 | 107 | 442 | 25 |
| 30 Jun 23 | 1,043 | 111 | 451 | 25 |
| 31 Mar 23 | 1,001 | 103 | 425 | 19 |
| 31 Dec 22 | 974 | 101 | 424 | 18 |
| 30 Sep 22 | 958 | 98 | 404 | 17 |
| 30 Jun 22 | 917 | 96 | 388 | 15 |
| 31 Mar 22 | 911 | 96 | 399 | 14 |
| 01 Jan 22 | 887 | 93 | 391 | 14 |
| 30 Sep 21 | 842 | 86 | 388 | 14 |
| 30 Jun 21 | 834 | 89 | 377 | 13 |
| 31 Mar 21 | 764 | 87 | 348 | 13 |
| 31 Dec 20 | 670 | 79 | 309 | 13 |
| 30 Sep 20 | 626 | 80 | 296 | 12 |
| 30 Jun 20 | 565 | 66 | 291 | 13 |
| 31 Mar 20 | 571 | 70 | 298 | 13 |
| 31 Dec 19 | 611 | 72 | 326 | 13 |
| 30 Sep 19 | 587 | 76 | 321 | 8 |
| 30 Jun 19 | 564 | 72 | 307 | 10 |
| 31 Mar 19 | 516 | 67 | 295 | 9 |
| 31 Dec 18 | 489 | 65 | 279 | 8 |
| 30 Sep 18 | 442 | 57 | 249 | 9 |
| 30 Jun 18 | 424 | 56 | 234 | 9 |
| 31 Mar 18 | 404 | 46 | 216 | 8 |
| 31 Dec 17 | 377 | 44 | 200 | 7 |
| 30 Sep 17 | 369 | 49 | 182 | 4 |
| 30 Jun 17 | 333 | 44 | 165 | 0 |
| 31 Mar 17 | 305 | 40 | 147 | 0 |
| 31 Dec 16 | 305 | 40 | 143 | 0 |
| 31 Dec 15 | 256 | 43 | 114 | 0 |
| 31 Dec 14 | 246 | 40 | 124 | 0 |
| 31 Dec 13 | 227 | 33 | 118 | 0 |
Quality Earnings: 002864 has high quality earnings.
Growing Profit Margin: 002864's current net profit margins (12.4%) are higher than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002864's earnings have grown by 11.1% per year over the past 5 years.
Accelerating Growth: 002864's earnings growth over the past year (16.9%) exceeds its 5-year average (11.1% per year).
Earnings vs Industry: 002864 earnings growth over the past year (16.9%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 002864's Return on Equity (7.8%) is considered low.